secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-09-08T20:50:29+00:00
Accession:  0001213900-26-098071
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay signs federal distribution deal with Lovell for SDVOSB set-aside markets
--------------------------------------------------------------------------------

- Exclusive SDVOSB set-aside distributor for VA, DoD, IHS procurements; non-exclusive rights on open-market federal/state/local deals.
- One-time $5,500 establishment fee paid; Lovell earns ~15% distribution fee on gross federal catalog sales plus 2% for DAPA prime vendor sales.
- Two-year initial term, auto-renewing annually unless 90-day notice; termination rights for default, bankruptcy, or $100K+ judgments.
- Deal signed Sep 1, 2026; press release Sep 8, 2026; partnership precedes FDA clearance, Symphony still investigational.
- Lovell provides access to VA FSS, GSA Advantage, MAS, ECAT, DAPA; co-marketing targets VHA ($165.1B FY2026 budget) and DoD/DHA ($64B).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026098071/0001213900-26-098071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026098071/ea0304864-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-098071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer